Vir Biotechnology, Inc. (VIR)Healthcare | Biotechnology | San Francisco, United States | NasdaqGS
9.72 USD
-0.24
(-2.410%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 3:28 a.m. EDT
The immediate outlook is defined by a stark divergence between a temporary catalyst and a deteriorating business reality. While recent headlines regarding a strategic collaboration with Astellas and positive cancer data have sparked a surge, the underlying fundamentals tell a different story. The company has endured five consecutive years of negative annual returns, with the stock price collapsing nearly 88% over the last half-decade. This multi-year decline is a powerful signal that the market has already priced out the risks associated with the company's inability to generate sustainable revenue or profits. The negative free cash flow and negative return on equity further confirm that the core business is currently consuming capital rather than generating it. Although the upcoming public offering and new partnership provide a necessary lifeline and potential short-term upside, they do not yet constitute a turnaround of the underlying enterprise quality. Investors should view the recent price action as a reaction to specific news events rather than a validation of a robust long-term investment thesis. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.068524 |
| AutoARIMA | 0.069634 |
| AutoETS | 0.069634 |
| AutoTheta | 0.076245 |
| MSTL_57 | 0.094417 |
| MSTL_126 | 0.097986 |
| MSTL_57_126 | 0.139350 |
Forecast horizon: 60 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 39% |
| H-stat | 0.71 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.242 |
| Excess Kurtosis | -1.06 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 11.76 |
| Revenue per Share | 0.465 |
| Market Cap | 1,639,297,152 |
| Forward P/E | -4.18 |
| Beta | 1.62 |
| Website | https://www.vir.bio |
As of July 11, 2026, 3:28 a.m. EDT: Speculators are positioning defensively with heavy put volume relative to calls, particularly at the $8 strike where open interest dominates both sides. While there is some call activity at $14 for October, the overwhelming majority of open interest sits in-the-money for puts, suggesting a floor at current levels rather than a breakout expectation. Implied volatility is elevated, reflecting uncertainty around the upcoming public offering and clinical data.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.81090903 |
| Address1 | 1,800 Owens Street |
| Address2 | Suite 900 |
| All Time High | 141.01 |
| All Time Low | 4.155 |
| Ask | 12.33 |
| Ask Size | 2 |
| Audit Risk | 3 |
| Average Daily Volume10 Day | 2,205,930 |
| Average Daily Volume3 Month | 1,904,657 |
| Average Volume | 1,904,657 |
| Average Volume10Days | 2,205,930 |
| Beta | 1.62 |
| Bid | 7.02 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 5.487 |
| City | San Francisco |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 9.72 |
| Current Ratio | 7.11 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 9.91 |
| Day Low | 9.52 |
| Debt To Equity | 11.76 |
| Display Name | Vir Biotechnology |
| Earnings Call Timestamp End | 1,778,099,400 |
| Earnings Call Timestamp Start | 1,778,099,400 |
| Earnings Timestamp | 1,778,097,600 |
| Earnings Timestamp End | 1,785,960,000 |
| Earnings Timestamp Start | 1,785,960,000 |
| Ebitda | -451,048,992 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.79 |
| Enterprise To Revenue | 19.216 |
| Enterprise Value | 1,258,577,152 |
| Eps Current Year | -1.3734 |
| Eps Forward | -2.32325 |
| Eps Trailing Twelve Months | -3.13 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 9.4031 |
| Fifty Day Average Change | 0.31690025 |
| Fifty Day Average Change Percent | 0.033701677 |
| Fifty Two Week Change Percent | 81.090904 |
| Fifty Two Week High | 11.66 |
| Fifty Two Week High Change | -1.9399996 |
| Fifty Two Week High Change Percent | -0.16638075 |
| Fifty Two Week Low | 4.155 |
| Fifty Two Week Low Change | 5.565 |
| Fifty Two Week Low Change Percent | 1.3393501 |
| Fifty Two Week Range | 4.155 - 11.66 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,570,800,600,000 |
| Float Shares | 128,760,723 |
| Forward Eps | -2.32325 |
| Forward P E | -4.1837945 |
| Free Cashflow | -214,927,632 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 367 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Gross Profits | -371,204,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.065910004 |
| Held Percent Institutions | 0.80713 |
| Implied Shares Outstanding | 168,651,974 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California. |
| Long Name | Vir Biotechnology, Inc. |
| Market | us_market |
| Market Cap | 1,639,297,152 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_419881198 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -442,716,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,639,297,187 |
| Number Of Analyst Opinions | 9 |
| Open | 9.81 |
| Operating Cashflow | -446,051,008 |
| Operating Margins | 4,592.4136 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 415 906 4324 |
| Pre Market Change | -0.11000061 |
| Pre Market Change Percent | -1.1316935 |
| Pre Market Price | 9.61 |
| Pre Market Time | 1,784,019,560 |
| Previous Close | 9.96 |
| Price Eps Current Year | -7.077327 |
| Price Hint | 2 |
| Price To Book | 1.7714598 |
| Price To Sales Trailing12 Months | 25.029348 |
| Profit Margins | 0.0 |
| Quick Ratio | 6.52 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.24 |
| Regular Market Change Percent | -2.40964 |
| Regular Market Day High | 9.91 |
| Regular Market Day Low | 9.52 |
| Regular Market Day Range | 9.52 - 9.91 |
| Regular Market Open | 9.81 |
| Regular Market Previous Close | 9.96 |
| Regular Market Price | 9.72 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 1,895,316 |
| Return On Assets | -0.24786 |
| Return On Equity | -0.47692 |
| Revenue Per Share | 0.465 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 168,651,974 |
| Shares Percent Shares Out | 0.113800004 |
| Shares Short | 19,192,724 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 18,316,762 |
| Short Name | Vir Biotechnology, Inc. |
| Short Percent Of Float | 0.115200005 |
| Short Ratio | 8.17 |
| Source Interval | 15 |
| State | CA |
| Symbol | VIR |
| Target High Price | 30.0 |
| Target Low Price | 16.0 |
| Target Mean Price | 21.55556 |
| Target Median Price | 21.0 |
| Total Cash | 476,299,008 |
| Total Cash Per Share | 2.824 |
| Total Debt | 95,579,000 |
| Total Revenue | 65,495,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.13 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 7.8001 |
| Two Hundred Day Average Change | 1.9199004 |
| Two Hundred Day Average Change Percent | 0.24613793 |
| Type Disp | Equity |
| Volume | 1,895,316 |
| Website | https://www.vir.bio |
| Zip | 94,158 |